ImpediMed Limited

Suite 31C, 12-18 Tryon Rd
Lindfield NSW 2070
Australia

E: investorrelations@impedimed.com
W: impedimed.com

26 June 2026

Companies Announcements Office
Australian Securities Exchange

Update on Options and Holding Statements

ImpediMed Limited (ASX: IPD) (**ImpediMed** or the **Company)** refers to its recent capital raising announced on 4 May 2026 which included the issue of options (the Attaching Options and Follow-On Options) to participants in the capital raising. Shareholders approved the issue of securities under the capital raising (including the options) at a shareholders meeting held on 11 June 2026.

Quotation of Attaching Options and Follow-On Options

Under the terms of the Attaching Options and the Follow-On Options, which were disclosed in the prospectus and notice of meeting, the Company sought quotation of both the Attaching Options and Follow-On Options.

The ASX granted quotation of the Attaching Options on 18 June 2026. Following a period of engagement between ASX and the Company, ASX has exercised its discretion to not grant quotation of the Follow-On Options.

The Attaching Options remain quoted under ASX code IPDO and are currently tradeable. The Follow-On Options have been issued to investors and can be transferred off-market.

The Company is assessing the courses of actions available to it and will provide a further update to investors in the upcoming week.

Option terms

Investors should refer to the prospectus for further information on the Attaching Options and Follow-On Options. In particular, the prospectus outlines that:

- the Attaching Options and Follow-On Options are not stapled;
- purchasing an Attaching Option on-market does not carry an entitlement to a Follow-On Option, each must be acquired independently; and

- Follow-On Options may only be exercised by a holder of Attaching Options following a valid exercise of those Attaching Options.

Holding statements

The dispatch of holding statements in respect of both the Attaching Options and Follow-On Options was placed on hold to ensure that they accurately reflect the status of these options following the outcome of the Company's discussions with ASX. The Company will provide a further update on holding statements in the upcoming week.

For more information, contact Investor Relations at investorrelations@impedimed.com.

Approved for release by the Board of ImpediMed Limited

About ImpediMed

Headquartered in Sydney, Australia with US and European operations, ImpediMed is a medical technology company that uses bioimpedance spectroscopy (BIS) technology to generate powerful data to maximise patient health. ImpediMed produces the SOZO® Digital Health Platform, which is FDA-cleared, CE-marked, and ARTG-listed for multiple indications, including lymphoedema, heart failure, and protein calorie malnutrition and sold in select markets globally.

In March 2024, the NCCN Clinical Practice Guidelines In Oncology (NCCN Guidelines®) for Survivorship continue to reference bioimpedance spectroscopy as the recommended objective tool to screen at-risk cancer patients for early signs of lymphoedema. With the SOZO Digital Health Platform and L-Dex®, ImpediMed is the only company to offer FDA-cleared technology that uses bioimpedance spectroscopy for the clinical assessment of lymphoedema. The connected digital health platform and large, attractive cancer-related lymphoedema market present an opportunity for continued strong growth through ImpediMed's SaaS subscription-based business.

For more information, visit www.impedimed.com.

Forward looking statements

This announcement contains or may contain forward-looking statements that are based on ImpediMed Limited (ImpediMed) management's beliefs, assumptions and expectations and on information currently available to management.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to our ability to expand sales and market acceptance in the US and Australia including our estimates of potential revenues, costs, profitability and financial performance; our ability to develop and commercialise new products including our ability to obtain reimbursement for our products; our expectations with respect to our clinical trials, including enrolment in or completion of our clinical trials and our associated regulatory submissions and approvals; our expectations with respect to the integrity or capabilities of our intellectual property position. Any forward-looking statements, including projections, guidance on future revenues, earnings and estimates, are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance.

While management has prepared this information based on its current knowledge and understanding and in good faith, there are risks and uncertainties involved which could cause actual results to differ from projections. You should not place undue reliance on forward-looking statements which speak only as of the date when made. Except as required by law, ImpediMed does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. ImpediMed may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements and no representation, warranty or assurance (express or implied) is given or made in relation to any forward-looking statement by any person (including ImpediMed Limited).